amiodarone has been researched along with Sclerosis, Systemic in 1 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pirfenidone is an antifibrotic agent potentially effective for IPF therapy, and preclinical and available clinical data support its use in IPF." | 6.43 | Pirfenidone for the treatment of idiopathic pulmonary fibrosis. ( Antoniu, SA, 2006) |
| "Pirfenidone is an antifibrotic agent potentially effective for IPF therapy, and preclinical and available clinical data support its use in IPF." | 2.43 | Pirfenidone for the treatment of idiopathic pulmonary fibrosis. ( Antoniu, SA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antoniu, SA | 1 |
1 review available for amiodarone and Sclerosis, Systemic
| Article | Year |
|---|---|
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell | 2006 |